Table 1 Patient demographics, disease characteristics and clinical follow-up

From: Early engraftment and full-donor chimerism after single-cord blood plus third-party donor dual transplantation in patients with high-risk acute leukemia

 

Sex

Age

Weight

Primary disease

Previous HCT

Previous chemotherapy

Disease status at

Engraftment

GVHD

Follow-up

      

treatments

UCB–TPD transplant

Neutrophils >0.5 × 10 9 /L

Platelets >20 × 10 9 /L

Acute

Chronic

Months

Status

1

M

53

62

AML secondary to MDS

No

IDICE x2, Mit-AraC x1

First CR

17

46

No

No

51

Alive-CR

2

F

52

95

AML/RAEBt (22% blasts)

No

IDICE x1, FLAG-Ida x1, Azcitidine x9

First PR (8% blasts)

17

19

No

No

43

Alive-CR

3

F

64

66

AML Flt3-ITD

No

IDICE x1, Mit-AraC x1

First CR

10

12

No

No

7

Dead in CR

4

M

62

68

RAEB-II (17% blasts)

No

IDICE x1, Mit-AraC x1

First CR

10

21

Grade II; cutaneous

No

33

Alive-CR

5

F

37

71

AML Flt3-ITD

No

Induction trial CALGB10603, FLAG-Ida x2

First CR

12

16

No

No

33

Alive-CR

6

M

48

58

AML

MAC sibling allo-HCT (7 years before)

IDICE x2, High doses AraC x1, allo-HCT, FLAG-Ida x2

Aplasia (22% blasts)a

12

95

Grade III; cutaneous

Limited

16

Dead in CR

7

F

32

99

AML Flt3-ITD, trisomy 5

No

IDICE x1, FLAG-Ida x2

First CR

12

105

No

No

19

Dead in Relapse

8

F

40

56

AML

Autologous HCT (8 months before)

IDICE x1, Mit-AraC x1, Autologous HCT, FLAG-Ida x1

Second CR

10

33

Grade II; cutaneous

No

22

Alive-CR

9

M

34

74

AML

No

IDICE x1, Mit-AraC x1, FLAG-Ida x1

Second CR

14

84

No

No

19

Alive-CR

10

M

20

78

Precursor B- ALL

No

ALL IR-Ind x1, ALL HR-Int x1, ALL 1st consol x1, FLAG-Ida x2

First CR

12

16

No

No

15

Alive-CR

11

M

30

104

Precursor B-ALL

No

ALL HR-Ind x2, ALL 1 st consol x2, ALL 2nd consol x2, ALL 3rd consol x2, FLAG-Idax2

Second CR

11

19

Grade II; cutaneous

No

15

Alive-CR

12

M

50

80

AML

RIC MUD allo-HCT (28 months before)

IDICE x2, Mit-AraC x1, MUD allo-HCT, FLAG-Ida x2

Second CR

12

23

No

No

6

Dead in CR

13

F

45

67

Phi+ ALL

No

Phi + ALL Ind, Phi + ALL 1st consol

First CR

11

23

Grade II; cutaneous

No

4

Alive-CR

  1. Abbreviations: ALL 1st consol: first block consolidation ALL chemotherapy consisting of dexamethasone (decreasing doses days 1–8), vincristine (1.5 mg/m2 days 1 and 8), MTX (3 g/m2 24 h infusion on day 1), cytarabine (2 g/m2 b.i.d. day 5), L-asparaginase (25 000 UI/m2 day 5) and mercaptopurine (100 mg/m2 days 1–5); ALL 2nd consol: second block consolidation ALL chemotherapy consisting of dexamethasone (decreasing doses days 1–8), vincristine (1.5 mg/m2 days 1 and 8), MTX (3 g/m2 24 h infusion on day 1), CY (150 mg/m2 days 1–5), L-asparaginase (25 000 UI/m2 day 5) and mitoxantrone (12 mg/m2 day 5); ALL 3rd consol: third block consolidation ALL chemotherapy consisting of dexamethasone (decreasing doses days 1–8), cytarabine (2 g/m2 b.i.d. days 1–2), VM-26 (150 mg/m2 days 3–4) and L-asparaginase (25 000 UI/m2 day 5); ALL HR-Ind: High-risk induction ALL chemotherapy consisting of vincristine (1.5 mg/m2 days 1 and 8), DNR (60 mg/m2 days 1 and 8) and prednisone (60 mg/m2 days 1–14); ALL HR-Int: High-risk intensification ALL chemotherapy consisting of vincristine (1.5 mg/m2 days 15 and 22), mitoxantrone (12 mg/m2 days 15–17), cytarabine (2 g/m2 b.i.d. days 18 and 19) and prednisone (60 mg/m2 days 15–27); ALL IR-Ind: Intermediate risk induction ALL chemotherapy consisting of vincristine (1.5 mg/m2 days 1 and 8), DNR (30 mg/m2 days 1 and 8) and prednisone (60 mg/m2 days 1–14); AML; CR; F=female; FLAG-Ida=salvage chemotherapy consisting of fludarabine (30 mg/m2 on days 1, 2, 3, 4), cytarabine (2 g/m2 on days 1–4), idarubicin (10 mg/m2 on days 1, 2, 3); HCT=hematopoietic cell transplant; IDICE=AML induction chemotherapy consisting of idarubicin (12 mg/m2 on days 1, 3, 5), cytarabine 500 mg/m2 twice daily on days 1, 3, 5, 7), and etoposide (100 mg/m2 on days 1, 2, 3); ITD=internal tandem duplication; M=male; MAC=myeloablative conditioning; MDS=myelodysplastic syndrome; Mit-AraC=AML consolidation chemotherapy consisting of cytarabine (500 mg/m2 b.i.d. days 1–6) and mitoxantrone (12 mg/m2 days 4-6); MUD=matched unrelated donor; Phi+ALL: Phi + ALL; Phi+ALL 1st consol: Ph+consolidation ALL chemotherapy consisting of mercaptopurine 50 mg/m2, days 1–7, 28–35 and 56–63; MTX 1.5 g/m2 24 h infusión days 1, 28 and 56; etoposide 100 mg/m2 b.i.d. days 14 and 42; cytarabine 1000 mg/m2 b.i.d. days 14,15, 42 and 43, imatinib 600 mg/d since day 1 and up to 15 days before SCT and intrathecal chemotherapy days 1, 28 and 56; Phi+ ALL Ind: Ph+ induction ALL chemotherapy consisting of imatinib 600mg/d, vincristine (1.5mg/m2 days 1, 15 and 22), DNR (45 mg/m2 days 1,8,15 and 22) and prednisone (60 mg/m2 days 1–27); intrathecal chemotherapy; PR=partial response; precursor B-ALL=precursor B-ALL; RAEB=refractory anemia with excess blasts; RAEBt=RAEB in transformation (20–30% blasts); RIC=reduced intensity conditioning.
  2. aAfter refractoriness to a 1st FLAG-Ida (22% blasts), the UCB–TPD dual transplant was performed in aplasia, 2 weeks after a 2nd FLAG-Ida.
Back to article page